Although EGFR is reported to be a major driver oncogene in lung cancer in Asia, especially adenocarcinoma, the exact proportion of Chinese NSCLC patients with EGFR mutations varies by report, and the difference may be related to the limited number of patients previously evaluated (3, 15). This evidence concerns the gene EGFR and lung cancer.